bluuebunny/crossref_metadata_2025_split huggingface dataset:
Plasma phenylalanine: Tyrosine ratios during high‐dose methotrexate‐citrovorum “rescue”
Authors: Hilton Mary A. , Patel Chandrakant C. , Bertolone Salvatore J. , Kmetz Donald R. , Clark Larry W. 
Published: February 2007

AbstractWe have measured phenylalanine and tyrosine in the plasma of patients with osteogenic sarcoma undergoing chemotherapy with high‐dose methotrexate (HDMTX) citrovorum factor rescue (CFR). During 14 treatments in six different patients, the phenylalanine to tyrosine ratio (PHE/TYR) at 21 to 38 hours was elevated over pretreatment levels. The observed increase in plasma phenylalanine is attributed to inhibition by MTX of the phenylalanine hydroxylase system of the liver, which is not folate‐dependent and thus is not corrected by administration of CF. A post‐infusion increase in PHE/TYR of 571% after 22 hours in one patient and of 410% after 30 hours in another were associated with marked MTX toxicity. The greatest increase in PHE/TYR seen in a patient who did not experience toxicity was was 249% in 21 hours. Thus, in this group of patients, there appears to be a correlation between evidence of clinical MTX toxicity and the magnitude of the percentage increase in PHE/TYR in the plasma, which indicates inhibition of a liver enzyme and thus reflects the intracellular concentration of MTX.
Restaging laparotomy in the management of the non‐Hodgkin lymphomas
Authors: Aisner Joseph , Wiernik Peter H. 
Published: February 2007

AbstractThe intensity of treatment and the extent of restaging necessary to document the level of response to therapy in patients with non‐Hodgkin lymphoma (NHL) remains controversial. One hundred patients with advanced non‐Hodgkin lymphoma were randomized to treatment with cyclophosphamide, vincristine, plus prednisone or cyclophosphamide, doxorubicin, vincristine, plus prednisone combination chemotherapy. After induction therapy sequential noninvasive restaging including lymphangiogram and 67gallium scan yielded 33 patients in clinical complete remission and 38 patients in partial remission. Twenty of these 38 patients in partial remission had complete normalization of all clinical and chemical tests (“apparent” clinical partial remission); however, lymphangiogram, gallium scan, abdominal sonogram, or abdominal CAT scan remained abnormal. In these 20 patients in “apparent” clinical partial remission, exploratory laparotomy was performed to further assess disease status. Laparotomy revealed evidence of residual disease in only four patients (20%). When correlated with the laparotomies the accuracy of repeat lymphangiograms and gallium scans was 17% and 50%, respectively. Thus, restaging lymphangiogram and gallium scan in NHL patients in “apparent” clinical partial remission are inaccurate, and “second look” operations are recommended for accurate appraisal of response to therapy. The assessment of true complete remission should help define the role of aggressive treatment.
Metastatic epidural tumors in children
Authors: Ch'ien Lawrence T. , Kalwinsky David K. , Peterson Gregory , Pratt Charles B. , Murphy Sharon B. , Hayes F. Ann , Green Alexander A. , Hustu H. Omar 
Published: February 2007

AbstractSpinal cord compression is a rare but serious complication of malignant diseases in children. Epidural cord compression was noted in 81 patients within the past 17 years at this center. The complication developed at different times during the course of the primary disease. For 29 of our patients, cord dysfunction was one of the initial signs of cancer—Ewing sarcoma, neuroblastoma, Hodgkin disease, and malignant lymphoma. By contrast, for most of the patients with osteosarcoma and rhabdomyosarcoma, it appeared later in their clinical course.The treatment outcome of patients who were paraplegic with complete loss of sensory function for ≫48 hours was poor. Only four of 22 in this group became ambulatory. Ten patients with osteosarcoma did not undergo laminectomies because they all had multiple metastases and terminal disease. Paraplegia developed in all ten. There was no difference in ambulatory rates among other patients, with or without laminectomies.
Hepatic artery infusion with 5‐fluorouracil and mitomycin‐c in metastatic colorectal carcinoma phase ii study
Authors: Theodors Asgeir , Bukowski Ronald M. , Lavery Ian , Hewlett James S. , Livingston Robert B. , Buonocore Edward 
Published: February 2007

AbstractThirty‐two patients with hepatic metastases colorectal carcinoma were treated with hepatic artery infusion (HAI) employing 5‐fluorouracil (5‐FU) and mitomycin‐C (mito‐C). Catheters were placed percutaneously via the femoral artery. Two schedules were employed: (I) 5‐FU 1,200 mg/m2 IA (D1‐4) and mito‐C 8 mg/m2 IA (D1 +D4); (2) 5‐FU 1,200 mg/m2 IA (D1‐6) and mito‐C 8 mg/m2 IA (D1 +D4). Courses were repeated every 4 weeks. Thirty patients with measurable disease were evaluable, 22 received schedule I and 8 patients schedule II. Complete response occurred in two patients (6.7%) and partial response in 13 patients (43.3%). Five patients (16.7%) had minimal regression. The overall response rate was 66.7%. Median survival of all patients from start of treatment was 11.2 months. Median survival of responders and nonresponders was 12.4 months and 4.6 months, respectively (P <0.05). No differences in response rates, duration of response, or survival was seen between the two schedules. Drug toxicity was moderate to severe, but morbidity of HAI per se was minimal. Intermittent HAI of 5‐FU and mito‐C is a well‐tolerated treatment modality associated with few serious complications. The response rate, duration of response, and the survival is comparable to continuous HAI infusion of 5‐FU or floxuridine (FUDR). As given in this study, mito‐C did not appear to provide added benefit.
Metastatic adenocarcinoma of unknown primary site: Analysis of 245 patients seen at the johns hopkins hospital from 1965‐1979
Authors: Markman Maurie 
Published: February 2007

AbstractA retrospective review of 245 patients with metastatic adenocarcinomas of unknown primary site (ACUP) seen at The Johns Hopkins Hospital from 1965‐1979 was undertaken. The median survival was 3.1 months. Age, sex, race, and year of diagnosis did not appear to influence survival. Patients having their major site(s) of disease above the diaphragm experienced a significantly longer survival than patients whose disease was below the diaphragm (5.3 versus 2.3 months, P < 0.05). As a group, patients treated with chemotherapy had no improvement in survival. However, the small number of patients treated with either cyclophosphamide or doxorubicin or both drugs had a median survival of greater than 9 months compared to 2.6 months for untreated or local radiotherapy‐treated patients and 3.2 months for patients treated with 5‐fluorouracil.
Prolonged survival of patients with extrapulmonary small cell carcinoma arising in the neck
Authors: Kasimis Basil S. , Wuerker Raymond B. , Malefatto Jerry P. , Moran Edgar M. 
Published: February 2007

AbstractTwo patients with extrapulmonary small cell carcinoma localized in the neck survived for more than two‐years without systemic therapy. This suggests that there may be a subset of small cell carcinomas characterized by slow growth, resulting in an indolent clinical course. By light and electron microscopy, we were unable to identify features of this indolent form which differ from those of the aggressive form of pulmonary or extrapulmonary small cell carcinoma.
Lymphoblastic lymphoma: Late relapse in childhood
Authors: Levine Peter L. , Berberich F. Ralph , Burke Jerome S. , Mott Martin G. , Wilbur Jordan R. 
Published: February 2007

AbstractThis report describes two children with lymphoblastic lymphoma who relapsed more than 21/2 years from diagnosis. Relapses occurred at seven and 20 months after completion of treatment. Their therapy consisted of an intensive pulse chemotherapy program combined with radiation therapy. Initial relapse after two years' treatment has been extremely rare in patients receiving contemporary chemotherapy programs, and two‐year survival without disease has been considered a cure. These cases illustrate that late relapses can occur after intensive chemotherapy and that two‐year disease‐free survival must not be interpreted as a complete cure.
Posttransfusion hepatitis in acute nonlymphocytic leukemia: Lack of a beneficial influence
Authors: Markman Maurie , Braine Hayden G. , Vaughan William P. 
Published: February 2007

AbstractThirty‐five patients with acute nonlymphocytic leukemia (ANNL) entered complete remission (CR) and survived 16 weeks following induction therapy with high‐dose timed sequential chemotherapy without maintenance therapy. These patients were analyzed to test the hypothesis that acute posttransfusion hepatitis (APTH) has a beneficial influence on the course of ANNL. Ten patients developed evidence of APTH while 25 did not. Median length of CR was 22 weeks for both groups while median survival was longer in patients not developing APTH (75 weeks vs 58 weeks) (P > 0.5). Possible explanations for the discrepancy between these results and those previously reported are discussed.
Growth in children with acute lymphocytic leukemia: A pediatric oncology group study
Authors: Berry D. H. , Elders M. J. , Crist W. M. , Land V. , Lui V. , Sexauer A. C. , Dickinson L. 
Published: February 2007

AbstractWe have studied 127 children from 5 participating institutions as to the effect of acute lymphoblastic leukemia (ALL) or the therapy used in the treatment of ALL on growth, growth hormone concentrations, and somatomedin activity. The study (SWOG No. 7581) was initiated in December 1975 and was closed to new entry in September 1979 and to data collection in February 1981. Heights, weights, and blood samples for growth hormone and somatomedin activity were obtained at the time of initial diagnosis and at intervals during the 55 months of observation. The percentage of boys <4 years of age below the 50th percentile is significantly greater than the expected 50% for both initial and final height (P<0.01). Girls <4 years appeared to have significantly different percentile height distribution from the normal for their final height measurement (P<0.05) but not for their initial height measurement. No other significant differences in the percentile height distribution were found. When growth rate, since time of diagnosis of ALL, is compared to the expected growth of normal children of the same age by linear regression analysis, there is a difference in the slope of the lines. Children with ALL are significantly shorter. The mean initial growth hormone and somatomedin concentration, 6.2 ng/ml and 1.3 μg/ml, respectively, vs mean remission growth hormone and somatomedin of 2.5 ng/ml and 1.1 μg/ml, respectively, were different. This was significant at P<0.01. The slope of the computed regression lines for multiple analysis of growth hormone and somatomedin were negative for more than 60% of the patients when compared to the initial concentration. These data suggest that a significant number of the children <4 years of age are short prior to the onset of therapy, and this persists throughout the course of their disease. Second, there is a reduction in growth rate during intensive therapy or the first year of the disease, with a normal growth rate thereafter. Third, growth hormone and somatomedin concentrations appear to be higher at the time of onset of the disease and decrease while on therapy.
Results of treatment of high risk childhood acute lymphoblastic leukemia
Authors: Kende George , El‐Najjar Khamis , Ben‐Bassat Isaac , Neuman Yoram , Ballin Ami , Ramot Bracha 
Published: February 2007

AbstractSixteen children with high risk acute lymphoblastic leukemia (ALL) who had one or more of the following risk factors: white cell count over 50 × 109/liter, mediastinal mass, age under 2 or over 10 years, extramedullary involvement, or T‐cell markers, were treated by a new protocol. All attained complete remission and 11 are still in their continuous first remission for 6‐53 months. High activity of adenosine deaminase (ADA) in the leukemic cells seems to be an independent risk factor, as in the high ADA level group, 4 out of 7 patients relapsed and died, while none of the 8 patients with low ADA levels relapsed or died.
A new chromosomal abnormality in a patient with acute myelomonocytic leukemia
Authors: Young Paul C. , Dickerman Joseph D. , Allen Elizabeth F. , Herklots A. Richard 
Published: February 2007

AbstractWe report a 15‐month‐old boy with acute myelomonocytic leukemia [French‐American‐British classification M4 (FAB‐M4)] whose leukemic cells demonstrated a translocation 46,XY, t(9;11)(p24;q12) that has not been described previously.
Radiation‐induced pneumothorax
Authors: Epstein David M. , Littman Philip , Gefter Warren B. , Miller Wallace T. , Raney R. Beverly 
Published: February 2007

AbstractPneumothorax is an uncommon complication of radiation therapy to the chest. The proposed pathogenesis is radiation‐induced fibrosis promoting subpleural bleb formation that ruptures resulting in pneumothorax. We report on two young patients with primary sarcomas without pulmonary metastases who developed spontaneous pneumothorax after irradiation. Neither patient had antecedent radiographic evidence of pulmonary fibrosis.
Comparison between X‐ray and bone scan detection of bone metastases in patients with rhabdomyosarcoma
Authors: Quddus Fauzia F. , Espinola Danilo , Kramer Sandra S. , Leventhal Brigid G. 
Published: February 2007

AbstractA comparison of radiographic and 99mTechnetium methyldiphosphonate scintigraphic evaluations for extent of skeletal disease was made retrospectively in 17 pediatric patients with Group III and IV rhabdomyosarcoma. Thirteen children had evidence of skeletal metastases. Of these, four exhibited multiple sites of blastic as well as lytic skeletal involvement on x‐rays that were not detected by bone scans: two at the time of initial diagnosis, and two at relapse in children with prior radiotherapy to involved bones. In three additional patients a greater extent of bony disease was evident on x‐rays than on bone scan. Neither the pathology of the tumor, lytic versus blastic quality of the bone lesion, nor lesion size per se was found to correlate with the failure to detect them on the bone scan. Although bone scans have greater sensitivity than x‐rays for the detection of metastatic bone involvement in several adult and pediatric neoplasms, in the case of rhabdomyosarcoma, the radiographic exam appears to be a more sensitive indicator in some patients and should be considered an essential study in the evaluation of skeletal involvement by this tumor.
Ependymoma, glioblastoma, and acute leukemia in a child
Authors: Goffman Thomas E. , Woo Shiao Y. , Manz Herbert , McCullough David , Sinks Lucius F. , Chun Byngkyu K. , Miller Robert W. 
Published: February 2007

AbstractA 5‐year‐old boy developed an ependymoma; 3 years later, after chemotherapy and radiotherapy, he developed glioblastoma multiforme and acute myeloblastic leukemia. His maternal grandmother had died at a young age of colon cancer. Since ependymoma is not known to predispose to other cancers, the unusual sequence of malignant disease may have been due to combined therapy in a susceptible host.
Continuous five‐day infusion of pala and 5FU: A pilot phase II trial
Authors: Presant Cary A. , Ardalan Bach , Multhauf Phyllis , Chan Clara , Staples Russell , Green Leland , Browning Scott , Carr Brian I. , Chang Fong‐Fu , Thayer William 
Published: February 2007

AbstractIn order to determine whether a simultaneous infusion of N‐(phospho‐n‐acetyl)‐L‐aspartic acid (PALA) was able to increase the rate of antitumor response to 5‐fluorouracil (5‐FU), a pilot study was conducted. Of 10 evaluable patients with previously drug‐untreated colorectal carcinoma, there were only two partial responses, lasting 2.3 and 1.6 months. No partial responses were observed in three evaluable patients with soft tissue sarcomas. The dose‐limiting toxicity was dermatitis. The simultaneous infusion of PALA and 5‐FU is not likely to produce a high number of antitumor responses of long duration in patients with colorectal carcinoma.
Leukemia presenting as central nervous disease without bone marrow involvement
Authors: Ganick Dorothy J. , Sondel Paul M. , Gilbert Enid F. , Borcherding Wayne 
Published: February 2007

AbstractA case of a nine‐year‐old boy who presented with central nervous system leukemia is described. This case was unusual because he presented without initial bone marrow involvement. Bone marrow involvement was documented 15 months after central nervous disease was diagnosed. Immunologic marker studies revealed that the spinal fluid blasts lacked definable B‐cell, pre‐B cell, T‐cell, and pre‐T cell surface markers. The marker studies helped to define the nature of the disease process.
Reactivity of subpopulations of mouse spleen cells to concanavalin a in vitro
Authors: Laing Calbert A. , Walters Curla S. 
Published: February 2007

AbstractSubpopulations of spleen cells of mice bearing virus‐induced mammary tumors were assessed for responsiveness to Concanavalin A (Con A) under in vitro xenogeneic and syngeneic culture conditions. When cultured with human A+ plasma (xenogeneic), spleen cells of normal, nontumor‐bearing BALB/c mice exhibited a high degree of synthesis as compared to unstimulated cells in response to Con A. Spleen cells of mice inoculated with tumor exhibited response exceeding that of their normal counterparts by 59%. When normal BALB/c sera (syngeneic) was used as the supplement, no response of normal spleen cells was observed upon stimulation by Con A; however, spleen cells from tumor bearing individuals demonstrated heightened activity. Tumor‐bearer spleen cell response to Con A of mice inoculated with 1 × 106 viable cells was biphasic. The peak of the first phase appeared as early as 10 days postinoculation and declined within 3 days after its appearance. The peak of the second phase appeared within 6 days following decline of the first and declined drastically within 3 days after its appearance. Coincidental with the onset of the second phase, the tumor became ulcerated, purulent, and necrotic. Both phases were predominantly T‐cell mediated.
Congenital ichthyosis and endodermal sinus tumor of the ovary in a ten‐year‐old child
Authors: Lopez Massimo , Papaldo Paola , Sciarretta Francesco , Barduagni Aldo 
Published: February 2007

AbstractAcquired ichthyosis is very likely to be associated with a malignancy, especially with Hodgkins disease. The association of congenital ichthyosis with malignant tumors has been so far reported only in two instances. Herein we report on a third case. Due to the small number of cases, no conclusion can be drawn about the correlations between the two diseases.
Gastrointestinal involvement with myeloma
Authors: Benson W. J. , Scarffe J. H. , Houwen B. , Crowther D. 
Published: February 2007

AbstractA patient with IgA‐k multiple myeloma is presented. There was initially a good response to chemotherapy but the patient later developed small intestinal obstruction. This was due to multiple polypoid plasmacytomas. The mesenteric nodes were also involved, and were found on immunofluorescence microscopy and flow cytometry with double fluorescent labelling to be composed of two separate populations of cells (IgA‐k and IgG‐k), one population having a diploid content of DNA and the other tetraploid. These two distinct cell populations differed in both proliferative characteristics and size. The findings are discussed and the literature relating to gastrointestinal involvement in plasma cell dyscrasias reviewed.
Psychosocial aspects of pediatric leukemia: From diagnosis through the first six months of treatment
Authors: Kupst Mary Jo , Schulman Jerome L. , Maurer Helen , Morgan Elaine , Honig George , Fochtman Dianne 
Published: February 2007

AbstractNewly diagnosed children with leukemia and their families were subjects of a longitudinal study to describe coping behaviors, to determine adequacy of coping, and to discover predictors of healthy coping with leukemia.Families were followed for six months during which time they were interviewed, completed tests and scales, and were rated by physicians, nurses, and psychosocial staff. Families showed a wide variety of reactions and coping behaviors. The data supported the hypothesis that most families cope well despite the stresses of the first six months post‐diagnosis. Based on physicians' ratings, psychosocial intervention appeared to be effective for mothers during the early outpatient phase of treatment. Age of child, previous coping, coping of other family members, a good support system, and lack of additional stresses were significantly correlated with healthy coping. The need for longitudinal assessment of coping was stressed.
Rhabdomyosarcoma of the larynx treated by laser surgery combined with radiotherapy and chemotherapy
Authors: Kedar A. , Kuten A. , Joachims H. Z. , Ben‐Arieh Y. , Yudelev M. 
Published: February 2007

AbstractThe case of a 6‐year‐old boy with rhabdo‐myosarcoma of the larynx, treated by laser surgery combined with external radiotherapy and chemotherapy, is presented. Using this treatment modality, cure was affected without comprising laryngeal function.
Chronic myelomonocytic leukaemia in infancy: A case report
Authors: Stockley R. J. , Eden O. B. 
Published: February 2007

AbstractThe case of an infant with the clinical and haematological features of chronic myelomonocytic leukaemia is reported. The infant presented with a peripheral blood monocyte count of 12,000 cell/mm3 (12.0 × 109 cell/L) but no lymphadenopathy, hepatomegaly, nor splenomegaly. No treatment was given for 14 months during which time the monocytosis persisted. Myeloblasts then appeared abruptly in the peripheral blood reaching a peak of 1,500,000 cell/mm3 (1,500 × 109/L). Cytotoxic Chemotherapy was initially successful but the blast soon became resistant and the child died. Chronic myelomonocytic leukaemia is usually associated with the elderly and the significance of this case is discussed.
Cytosine arabinoside induced liver damage: Histopathologic demonstration
Authors: Pizzuto Javier , Avilés Agustin , Ramos Ernesto , Cervera Jorge , Aguirre Jesús 
Published: February 2007

AbstractTwo patients with acute leukemia developed abnormal liver function tests after the administration of cytosine arabinoside. Other possibles causes for such abnormalities were not likely. In both patients a close chronologic relationship between the administration of the drug and the appearance of the laboratory abnormalities was noted. The liver damage was also documented by biopsy. To our knowledge this is the first time that the hepatotoxic effects of cytosine arabinoside are histologically demonstrated.
Skeletal scintigraphy and radiography at onset of acute lymphocytic leukemia in children
Authors: Clausen Niels , Gøtze Hans , Pedersen Aase , Riis‐Petersen JøRn , Tjalve Elsebet 
Published: February 2007

Abstract99mTechnetium skeletal scintigraphy performed at the time of diagnosis was compared with pain and radiographs in 24 children with acute lymphocytic leukemia. Localized intense uptake of the labeled compound in one or several metaphyses and increased uptake in diaphyses were typical findings by scintigraphy. The skeleton of each child was subdivided into 18 regions, and investigated for the presence of pain and for possible radiographic and scintigraphic abnormalities. In a total of 432 regions (18 regions in each of 24 children), pain was present in 23 regions, radiographic anomalies in 54 regions, and abnormal technetium uptake in 98 regions. Signs and symptoms were most often found in the lower extremities. Pain and radiographic or scintigraphic abnormalities were not regularly found in the same skeletal regions. The individual number of radiographic abnormalities was negatively correlated with age, whereas the number of regions with abnormal technetium uptake was positively correlated with age. No significant correlation was found between the number of abnormal scintigraphic or radiographic regions and the clinical outcome of the disease.